Lausanne, Switzerland-based Aesyra, a medical device company that develops oral appliance technologies to improve sleep, announced that it has secured $3M (approximately €2.7M) in a seed round of funding.
The funding round was led by Supermoon Capital, the world’s first fund focused on sleep tech, and deep tech investor Creadd Ventures, with participation from existing investor Zürcher Kantonalbank.
The capital infusion will help the company fund the development and commercialisation of its AesyBite line of products for accurate monitoring and treatment of sleep bruxism and sleep apnea.
Sleep bruxism is a sleep disorder often linked to sleep apnea, which affects nearly a billion people worldwide.
“This significant investment marks a pivotal moment for Aesyra,” said Marco Letizia, founder and CEO of Aesyra. “We are thrilled to partner with Supermoon Capital and Creadd Ventures, who share our vision of driving meaningful change within the sleep industry. With their support, we are well-positioned to accelerate the deployment of our groundbreaking solutions, ultimately improving patient outcomes and advancing healthcare practices.”
Aesyra: Accurately monitor and relieve sleep bruxism
Founded by Pietro Maoddi and Marco Letizia as a spin-off of the Federal Institute of Technology of Lausanne (EPFL) in 2017, Aesyra has developed a line of devices — AesyBite.
It uses proprietary sensors and algorithms that allow intraoral measurements of several factors during sleep and is capable of actively reducing bruxism and improving patients’ quality of life.
As per the company’s claims, the product has demonstrated over 70 per cent reduction in
bruxism activity for users.
Powering Aesyra’s AesyBite is a technology developed by EPFL researchers and algorithms that leverage over 10 years of sleep research data.
The investor
Supermoon Capital is the only venture capital firm in the world focused exclusively on the sleep technology market.
Based out of San Francisco, the VC partners with visionary innovators across the sleep market spectrum encompassing chronobiology, neurotech, biotech, pharmaceuticals, medtech, consumer interventions, and enterprise solutions.
As a part of the funding round, Masterson Leoni will join the Board of Directors of Aesyra.
“This significant investment marks a pivotal moment for Aesyra,” says Marco Letizia, founder and CEO of Aesyra. “We are thrilled to partner with Supermoon Capital and Creadd Ventures, who share our vision of driving meaningful change within the sleep industry. With their support, we are well-positioned to accelerate the deployment of our groundbreaking solutions, ultimately improving patient outcomes and advancing healthcare practices.”
01
Meet the 11 social innovators pitching at DNNL X Social Enterprise NL Launchpad Demo Day 2024